Market Cap 26.39M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 145,600
Avg Vol 203,346
Day's Range N/A - N/A
Shares Out 7.25M
Stochastic %K 62%
Beta 1.26
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
SmallCapGrowth
SmallCapGrowth Jun. 1 at 3:07 PM
$BCTX showing what investors want to see: 👉 Durable survival in late-stage cancer 👉 Biomarkers validating response 👉 Early Phase 3 momentum building In a space where options are limited, long-term survivor cohorts matter. #Biotech #ASCO2026 NEWS: https://bit.ly/3Se0RRi
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 2:47 PM
BriaCell Therapeutics Corp ( $BCTX ): CANCER STOCK NEWS: $BCTX delivers at AS... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177658440 via @Investors_Hub
0 · Reply
JediGreen
JediGreen Jun. 1 at 2:21 PM
$BCTX how much was trodelvy sold for - Google Search https://www.google.com/search?q=how+much+was+trodelvy+sold+for&sca_esv=5f802be1e67c425f&source=hp&ei=CZUdapunCu-mruEPkdrdkAc&biw=430&bih=721&oq=how+much+was+trodelvy&gs_lp=EhFtb2JpbGUtZ3dzLXdpei1ocCIVaG93IG11Y2ggd2FzIHRyb2RlbHZ5KgIIADIFECEYoAEyBRAhGKABMgUQIRigATIFECEYoAEyBhAAGBYYHjIFECEYnwVI29UCUJsMWJjIAnANeACQAQCYAaABoAGtGKoBBTE0LjE1uAEByAEA-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&sclient=mobile-gws-wiz-hp#lfId=ChxjMe
0 · Reply
TWBXX
TWBXX Jun. 1 at 2:15 PM
$BCTX Head‑to‑Head Reality Check Trodelvy (Gilead) — 3L+ MBC Median OS: ~12–13 months 12‑month survival: ~35–40% Toxicity: High (neutropenia, diarrhea, alopecia) Discontinuation rate: Meaningful Mechanism: ADC (TROP‑2), cytotoxic payload Bria‑IMT (BriaCell) — Phase 2, Phase 3 regimen Median OS: 16.6 months 12‑month survival: ~44–55% 24‑month survival: ~26–27% Toxicity: Very low TWiST/QoL: Better than chemo Mechanism: Immune‑activating cellular therapy + CPI
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 1:58 PM
CANCER STOCK NEWS: $BCTX delivers at ASCO 2026 ✅ 55% 1-year survival ✅27% 2-year survival ✅Heavily pre-treated metastatic breast cancer This is the kind of dataset that can re-rate a biotech. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:56 PM
$BCTX 07:43 on Jun. 01 2026 BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2 #tradeideas
0 · Reply
Kirubin
Kirubin Jun. 1 at 1:11 PM
$BCTX Endless money black hole! $2S coming up then RS again🫡🐏🐏🐏🐏👏🏽👏🏽
1 · Reply
Kirubin
Kirubin Jun. 1 at 1:08 PM
$BCTX done!
0 · Reply
SmallCapVoice
SmallCapVoice Jun. 1 at 12:26 PM
BriaCell $BCTX reported positive data at ASCO 2026, highlighting 55% 1-year survival and 27% 2-year survival in heavily pre-treated metastatic breast cancer patients using its Phase 3-selected Bria-IMT™ regimen. Early Phase 3 data also showed meaningful quality-of-life benefits and encouraging biomarker results. https://www.globenewswire.com/news-release/2026/06/01/3304255/0/en/briacell-presents-positive-clinical-data-at-asco-2026.html
0 · Reply
JediGreen
JediGreen Jun. 1 at 12:17 PM
$BCTX Wounder if we will see 4s filed this week.
2 · Reply
Latest News on BCTX
BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 3 hours ago

BriaCell Presents Positive Clinical Data at ASCO 2026


BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 15 hours ago

BriaCell Therapeutics Announces Pricing of Offering


BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 10 days ago

BriaCell announces data from Bria-IMT at ASCO 2026


BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 20 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients


BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 25 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial


BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026


BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 5 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS


BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR


BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 3 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting


BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data


Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?


BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering


What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?


BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%


BriaCell Therapeutics (BCTX) Launches $30M Public Offering

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering


BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering


BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

BCTX


BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 8 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BCTX


BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 10 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BCTX


SmallCapGrowth
SmallCapGrowth Jun. 1 at 3:07 PM
$BCTX showing what investors want to see: 👉 Durable survival in late-stage cancer 👉 Biomarkers validating response 👉 Early Phase 3 momentum building In a space where options are limited, long-term survivor cohorts matter. #Biotech #ASCO2026 NEWS: https://bit.ly/3Se0RRi
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 2:47 PM
BriaCell Therapeutics Corp ( $BCTX ): CANCER STOCK NEWS: $BCTX delivers at AS... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177658440 via @Investors_Hub
0 · Reply
JediGreen
JediGreen Jun. 1 at 2:21 PM
$BCTX how much was trodelvy sold for - Google Search https://www.google.com/search?q=how+much+was+trodelvy+sold+for&sca_esv=5f802be1e67c425f&source=hp&ei=CZUdapunCu-mruEPkdrdkAc&biw=430&bih=721&oq=how+much+was+trodelvy&gs_lp=EhFtb2JpbGUtZ3dzLXdpei1ocCIVaG93IG11Y2ggd2FzIHRyb2RlbHZ5KgIIADIFECEYoAEyBRAhGKABMgUQIRigATIFECEYoAEyBhAAGBYYHjIFECEYnwVI29UCUJsMWJjIAnANeACQAQCYAaABoAGtGKoBBTE0LjE1uAEByAEA-AEBmAIqoAKTG6gCHsICERApGIAEGLEDGNEDGIMBGMcBwgIIECkYgAQYsQPCAgUQKRiABMICCxApGIAEGMcBGK8BwgICECnCAgUQKRigAcICBhApGBYYHsICCxApGIAEGLEDGIMBwgILECkYgAQYkQIYigXCAgcQKRiABBgNwgIQEAAYAxi0AhjqAhiPAdgBAcICEBAuGIAEGNEDGEMYxwEYigXCAhEQLhiABBixAxjRAxiDARjHAcICCxAAGIAEGLEDGIMBwgILEC4YgAQY0QMYxwHCAg4QLhiABBixAxjRAxjHAcICDhAuGIAEGLEDGIMBGIoFwgILEC4YgAQYsQMYgwHCAgsQLhiABBiRAhiKBcICERAuGIAEGJECGNEDGMcBGIoFwgILEAAYgAQYkQIYigXCAhEQLhiABBiRAhjHARiKBRivAcICEBAAGIAEGLEDGEMYgwEYigXCAgUQABiABMICCBAuGIAEGLEDwgIJEAAYgAQYChgLwgIKEAAYgAQYyQMYCsICCxAuGIAEGMcBGK8BwgIHEAAYgAQYCsICDhAAGIAEGJECGLEDGIoFwgITEC4YgAQYsQMY0QMYQxjHARiKBcICChAAGIAEGEMYigXCAgcQLhiABBgKwgIWEC4YgAQYQxjHARiYBRiKBRidBRivAcICDBAAGIAEGLEDGAoYC8ICCBAAGIAEGKIEwgIFEAAY7wXCAg4QABiABBixAxiDARiKBcICCBAAGIAEGLEDwgIHEAAYgAQYDcICCBAAGAgYDRgewgILEAAYgAQYhgMYigWYAwzxBWnVs3AgppAOugYECAEYCpIHBTIwLjIyoAezxwGyBwQ3LjIyuAeYGsIHCDAuMy4zNi4zyAfUAYAIAA&sclient=mobile-gws-wiz-hp#lfId=ChxjMe
0 · Reply
TWBXX
TWBXX Jun. 1 at 2:15 PM
$BCTX Head‑to‑Head Reality Check Trodelvy (Gilead) — 3L+ MBC Median OS: ~12–13 months 12‑month survival: ~35–40% Toxicity: High (neutropenia, diarrhea, alopecia) Discontinuation rate: Meaningful Mechanism: ADC (TROP‑2), cytotoxic payload Bria‑IMT (BriaCell) — Phase 2, Phase 3 regimen Median OS: 16.6 months 12‑month survival: ~44–55% 24‑month survival: ~26–27% Toxicity: Very low TWiST/QoL: Better than chemo Mechanism: Immune‑activating cellular therapy + CPI
0 · Reply
SmallCapGrowth
SmallCapGrowth Jun. 1 at 1:58 PM
CANCER STOCK NEWS: $BCTX delivers at ASCO 2026 ✅ 55% 1-year survival ✅27% 2-year survival ✅Heavily pre-treated metastatic breast cancer This is the kind of dataset that can re-rate a biotech. #Biotech #StocksToWatch #Healthcare NEWS: https://bit.ly/3Se0RRi $LLY $JNJ $PFE @smallcapvoice @StuartSmithSCV
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 1:56 PM
$BCTX 07:43 on Jun. 01 2026 BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2 #tradeideas
0 · Reply
Kirubin
Kirubin Jun. 1 at 1:11 PM
$BCTX Endless money black hole! $2S coming up then RS again🫡🐏🐏🐏🐏👏🏽👏🏽
1 · Reply
Kirubin
Kirubin Jun. 1 at 1:08 PM
$BCTX done!
0 · Reply
SmallCapVoice
SmallCapVoice Jun. 1 at 12:26 PM
BriaCell $BCTX reported positive data at ASCO 2026, highlighting 55% 1-year survival and 27% 2-year survival in heavily pre-treated metastatic breast cancer patients using its Phase 3-selected Bria-IMT™ regimen. Early Phase 3 data also showed meaningful quality-of-life benefits and encouraging biomarker results. https://www.globenewswire.com/news-release/2026/06/01/3304255/0/en/briacell-presents-positive-clinical-data-at-asco-2026.html
0 · Reply
JediGreen
JediGreen Jun. 1 at 12:17 PM
$BCTX Wounder if we will see 4s filed this week.
2 · Reply
JediGreen
JediGreen Jun. 1 at 12:14 PM
0 · Reply
Orlandotrader
Orlandotrader Jun. 1 at 12:11 PM
$BCTX And this is why folks hate this company. Ridiculous Million Dollar raise after a previous 30 Million Raise!!! Really!
0 · Reply
BHWinehouse
BHWinehouse Jun. 1 at 11:55 AM
$BCTX Well would you look at that https://finance.yahoo.com/sectors/healthcare/articles/briacell-presents-positive-clinical-data-113000429.html
0 · Reply
rp6577
rp6577 Jun. 1 at 11:41 AM
$BCTX not that bad to be fair
0 · Reply
Ares77manoe
Ares77manoe Jun. 1 at 11:24 AM
$BCTX va bene
0 · Reply
Ares77manoe
Ares77manoe Jun. 1 at 11:24 AM
$BCTX time to add
1 · Reply
jfun1
jfun1 Jun. 1 at 11:19 AM
$BCTX no warrants is a positive change
0 · Reply
AHA_OHO
AHA_OHO Jun. 1 at 10:59 AM
$BCTX I said..
0 · Reply
BHWinehouse
BHWinehouse Jun. 1 at 10:20 AM
$BCTX Believe what you want, I see this relatively low offering as just a bridge to an expected catalyst they know is coming.
2 · Reply
MoeMaze
MoeMaze Jun. 1 at 6:14 AM
$BCTX !!!!!
0 · Reply
MoeMaze
MoeMaze Jun. 1 at 6:09 AM
$BCTX 🔁🤢🔁
0 · Reply
MoeMaze
MoeMaze Jun. 1 at 6:03 AM
$BCTX as expected ! #Crooks !
1 · Reply